Otsuka, Acucela JV Ready Phase III Trials Of Dry AMD Drug In Europe, U.S.
This article was originally published in PharmAsia News
Executive Summary
Otsuka Pharmaceutical is set to begin Phase III clinical trials in Europe and the United States with Acucela, a biotech begun by a Japanese ophthalmologist in the U.S. Otsuka is a major investor in the venture that has developed an orally delivered drug for the dry form of age-related macular degeneration.